Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
ELDN•Outlook
- Company expects current cash to fund operations into Q2 2027
Overview
- US biotech reported Q2 net loss widened yr/yr, driven by non-cash warrant liability changes
- Operating expenses for Q2 fell compared to the prior-year period
- Company expects cash and investments to fund operations into Q2 2027
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net Loss | $31.63 mln | ||
| Q2 Income from Operations | -$22.87 mln | ||
| Q2 Operating Expenses | $22.87 mln |
Result drivers
- Operating expenses - Q2 operating expenses declined yr/yr, mainly due to lower research and development spending
